Marapharm Ventures Inc. Congratulates Canada - First G7 nation to legalize adult-use of cannabis for recreational purposes
KELOWNA, BC, Oct. 17, 2018 /CNW/ - Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) ("Marapharm" or the "Company") shares its exhilaration with Canadians on this historic day of the legalization of recreational cannabis.
Health Canada has confirmed receipt of our amended, late-state ACMPR application.
We are strategically positioning ourselves to become a presence in the Canadian cannabis market. Our (10) 10,000 sq. ft bio-secure facilities (100,000 sq. ft) will aim to produce a pure organic cannabis flower using cultivation methods that will leave a small environmental footprint allowing us to produce at a lower cost.
The governmental agency Health Canada estimates annual demand in the country to be 926,000 kilograms, or about 2 million pounds. There's no reliable data on the exact supply of licensed recreational vendors, however the most recent estimates put the nation's supply of medical marijuana at 66,404 kilograms of dried cannabis.
https://www.cbc.ca/news/business/legal-cannabis-shortage-looms-1.4845816
"We have shared a common goal for the legalization of cannabis and today it is a reality. We are honoured to be a part of this revolution and now we are free to unlock the potential of this amazing plant." Linda Sampson, President and CEO
ABOUT MARAPHARM VENTURES INC.
Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.
SOCIAL MEDIA:
Facebook: facebook.com/marapham
Twitter: twitter.com/marapharm
STOCK EXCHANGES:
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQX, and in Europe, ticker symbol 2M0 on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.
Neither the CSE, the FSE nor the OTCQX® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQX® accepts responsibility for the adequacy or accuracy of this release.
MARIJUANA INDUSTRY INVOLVEMENT:
Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.
Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm's ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm's business is conducted in a manner consistent with state law and is in compliance with licensing requirements.
Copies of licenses are posted on Marapharm's website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward- looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward- looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
SOURCE Marapharm Ventures Inc.
www.marapharm.com or Linda Sampson, CEO 778-583-4476, email [email protected]
Share this article